Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

NCT02657889 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT02657889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02657889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Lead sponsor
Tesaro, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 15, 2016
Completion date
September 17, 2021
Enrollment
122 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, fallopian tube cancer, metastatic breast cancer, neoplasms, ovarian cancer, peritoneal cancer, stage iv breast cancer, triple negative breast cancer